Evaluation of clinical benefit of sacituzumab govitecan (SG) following enfortumab vedotin (EV) in advanced urothelial cancer (UC): Real-world experience. Cabozantinib in patients with locally advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results